Le TEC du groupe Stevanato au coeur du pôle de biotechnologie de Boston. Stevanato Group’ TEC in the heart of Boston biotech hub. FOCUS pour l’amélioration continue de son offre produit, l’expansion de sa propriété intellectuelle et le développement de nouvelles solutions pour répondre aux besoins du marché. LES FORCES DU GROUPE STEVANATO STEVANATO GROUP’S STRENGTHS Avec une croissance à deux chiffres qui a clôturé les résultats fin 2019, le groupe Stevanato a réalisé un chiffre d’affaires de 638,5 With a double-digit growth closing the results at the end of 2019, millions de dollars et poursuit sa croissance et son investissement the Stevanato Group achieved revenues of $638.5 million and conti- nues to grow and invest in the development of high value-added dans le développement de produits et de services à forte valeur products and services. The company recently approved a $447.8 ajoutée. La société a récemment approuvé un plan industriel million industrial investment plan in which the US TEC plays a d’investissements de 447,8 millions de dollars au sein duquel le TEC crucial role to ensure organic growth in the biotechnology segment. américain joue un rôle crucial pour assurer la croissance organique The Group also invests more than 4% of its annual turnover in Research & Development for continuous improvement of its pro- dans le secteur de la biotechnologie. Le groupe investit également duct offering, the expansion of its IPs and the development of new plus de 4 % de son chiffre d’affaires chaque année dans la R&D solutions to meet the needs of the market. 70 years of expertise stage formulations to the integration development. Thanks to the group's into delivery devices. For Paolo Patri, in-depth knowledge of glass, plastics With over 70 years of expertise in the chief technology officer of the Group, and rubber material science and its production of primary glass packa- by partnering up with American interdisciplinary team of technicians ging, Stevanato is uniquely positioned clients at an early stage, the TEC can and scientists in Italy, who has carried to guide biotech companies on one easily integrate into their value chain out a wide range of tests from packa- of the most critical decisions in their and thus anticipate challenges, come ging performance to its chemical analy- drug development program: choosing up with solid and viable solutions in sis, going through the container/content the primary glass container from early order to save time and resources for interaction and surface characterization, September - 2020 / The Pharmaceutical Post 03 19 SWEN